SETBP1 is a protein that has emerged as an important player in several blood cancers, including atypical chronic myeloid leukemia (aCML) and related myeloid malignancies. Somatic mutations in SETBP1 - meaning mutations that arise during a person's lifetime rather than being inherited - have been found in these cancers.
These cancer-associated mutations cluster in a specific part of the SETBP1 protein called the degron motif, a short sequence that normally signals the protein for rapid degradation. When this motif is mutated, the protein can no longer be degraded efficiently and accumulates to abnormally high levels in cells.
Previously, the main known consequence of SETBP1 accumulation was the inhibition of PP2A, a tumor-suppressor phosphatase enzyme. However, this mechanism alone did not explain all the effects of SETBP1 mutations, particularly those seen in a severe developmental syndrome called Schinzel-Giedion syndrome (SGS), where germline (inherited) SETBP1 mutations cause intellectual disability and multi-organ abnormalities.
SETBP1 also contains three AT-hook domains - protein structures known to bind to DNA in regions rich in the nucleotides adenine and thymine. This feature strongly suggested that SETBP1 might directly bind to DNA and influence gene activity, a role that had not been fully characterized before this study.
To study how SETBP1 interacts with the genome, the researchers created cell lines that stably express either the normal (wild-type) or the most common cancer-associated mutant form of SETBP1 (called G870S). They then used ChIP-Seq (chromatin immunoprecipitation followed by DNA sequencing) to map every location in the genome where SETBP1 binds.
ChIP-Seq works by chemically freezing protein-DNA interactions in the cell, then using antibodies to pull out only the DNA fragments bound by a specific protein, and finally sequencing those fragments to determine their genomic location. This provides a genome-wide, unbiased picture of where a protein acts.
To understand whether SETBP1 binding changes gene activity, the team also performed RNA-Seq (transcriptome sequencing), which measures the expression level of every gene in a cell. They compared gene expression in cells with no SETBP1, normal SETBP1, and mutant SETBP1.
Additional techniques included ATAC-Seq to measure chromatin accessibility (whether DNA is in an open, readable state), co-immunoprecipitation to identify proteins that physically interact with SETBP1, and in utero brain electroporation in mouse embryos to study the effects of SETBP1 mutations on brain development.
The ChIP-Seq experiments revealed that SETBP1 binds to 3,065 broad genomic regions, predominantly in areas rich in adenine and thymine (AT-rich sequences). The average AT content of SETBP1 binding regions was 65.8%, compared to 59% for the human genome overall, confirming that SETBP1 uses its AT-hook domains to recognize specific DNA sequences.
A consensus binding sequence was identified (AAAATAA/T), which closely resembles the binding motif of HMGA1 - a well-known AT-hook protein. This sequence is conserved across species (found in both human and mouse), suggesting the DNA-binding function of SETBP1 is evolutionarily important.
About 58-65% of SETBP1 binding sites were located near gene promoters - the regulatory regions at the start of genes that control their activation. However, SETBP1 also bound to enhancers, regions within genes (exons and introns), and intergenic regions, suggesting a broad regulatory role.
When the AT-hook domains were deleted from mutant SETBP1, the protein could no longer bind to DNA and could no longer activate its target genes. This confirmed that AT-hooks are essential for SETBP1's DNA-binding and gene-activating functions.
Beyond simply binding DNA, SETBP1 was found to recruit a set of proteins that modify the epigenetic state of the chromatin - the packaging around DNA that determines whether genes are accessible and active. This makes SETBP1 an epigenetic hub: a central organizer that brings together multiple chromatin-modifying proteins.
Specifically, SETBP1 was shown to directly interact with HCF1, KMT2A (also called MLL1), and PHF8. HCF1 is a core component of a histone-modifying complex. KMT2A is a well-known enzyme that adds activating chemical marks to histone proteins (H3K4 methylation), and PHF8 is a demethylase that removes repressive histone marks.
Where SETBP1 bound near gene promoters, there were increases in H3K4me2 and H3K9ac - chemical modifications on histones (the proteins that DNA wraps around) that are associated with active gene expression. Simultaneously, there were decreases in H4K20me1, a mark often associated with gene silencing.
This combination of histone modifications, along with increased chromatin accessibility as measured by ATAC-Seq, indicates that SETBP1 actively opens up chromatin at its target genes, making them more easily read and expressed by the cell's transcription machinery.
MECOM (also known as EVI1) is a transcription factor that is frequently overexpressed in myeloid leukemias and is associated with a very poor prognosis. It is often activated through chromosomal rearrangements in about 10% of acute myeloid leukemia (AML) cases and in myelodysplastic syndromes.
This study showed that SETBP1 directly binds to the MECOM promoter and activates its expression. Both ChIP-Seq data (showing physical binding) and RNA-Seq/quantitative PCR data (showing increased gene expression) confirmed this direct relationship.
To validate this finding in actual cancer patients, the researchers analyzed 32 cases of atypical chronic myeloid leukemia - 11 with SETBP1 mutations and 21 without. Patients with SETBP1 mutations had significantly higher MECOM expression (P = 0.0002), confirming the relevance of this pathway in human disease.
Beyond MECOM itself, the downstream target genes controlled by MECOM were also more active in SETBP1-mutant leukemias. This reveals a cascade effect: SETBP1 mutation leads to SETBP1 protein accumulation, which activates MECOM, which in turn activates a whole network of genes that drive leukemia cell growth and survival.
Gene ontology analysis of SETBP1 target genes revealed a striking enrichment for development-related biological processes, including nervous system development, brain morphogenesis, heart development, bone development, and stem cell maintenance.
This finding is biologically significant because it provides a molecular explanation for Schinzel-Giedion syndrome - a developmental disorder caused by germline SETBP1 mutations. SGS patients suffer from brain abnormalities, multi-organ defects, and abnormal neuronal layering. If SETBP1 mutations inappropriately activate developmental gene networks, this could disrupt the carefully timed gene expression programs that guide organ formation.
RNA-Seq analysis showed that cells expressing mutant SETBP1 had 2,687 differentially expressed genes. Of these, 43% were upregulated and 57% were downregulated. The upregulated genes bound directly by SETBP1 in their promoters were almost entirely activated (94.3%), confirming that SETBP1 acts primarily as a positive gene activator.
The same gene networks that are disrupted in SGS during brain development are also hijacked in leukemia to support abnormal cell growth. This highlights how the same molecular machinery can have completely different consequences depending on the cellular context and timing of SETBP1 activation.
To directly test the effect of SETBP1 mutations on brain development, researchers injected mutant SETBP1 (G870S) into mouse embryo brain cells using a technique called in utero electroporation - where an electric pulse drives DNA into specific brain cells in living embryos.
Just two days after introducing the mutant SETBP1, the affected cells were severely impaired in their ability to migrate outward through the developing cortex. Normal neurons travel from deep to superficial layers of the cortex in a stereotyped pattern; cells expressing mutant SETBP1 remained stuck in deep regions, with only a fraction reaching their proper destinations.
Five days after the procedure, control cells had migrated to the outer cortex and were contributing to the corpus callosum (the bridge connecting the two brain hemispheres). In contrast, 65% of cells with mutant SETBP1 remained in deep cortical tissue, compared to just 32% in controls.
Critically, when either the AT-hook DNA-binding domains or the HCF1-interaction domain were deleted from the mutant SETBP1, normal migration was largely restored. This directly proves that the epigenetic gene-activation function of SETBP1 - requiring DNA binding and protein complex assembly - is responsible for the neuronal migration defect.
This study unveils a previously unrecognized function of SETBP1: it is not merely a PP2A inhibitor but a bona fide transcription factor and epigenetic hub that directly controls gene expression by binding AT-rich DNA and assembling a chromatin-opening complex.
This newly discovered function provides a unified molecular explanation for two seemingly different diseases - blood cancer (through SETBP1 somatic mutations causing leukemia) and a developmental syndrome (through germline mutations causing Schinzel-Giedion syndrome). In both cases, the core problem is excess SETBP1 activity inappropriately activating developmental gene networks.
The identification of the SETBP1-HCF1-KMT2A-PHF8 complex as the effector of this transcriptional activation opens potential therapeutic avenues. Drugs that disrupt this complex - for example, inhibitors of KMT2A or PHF8 - could potentially suppress the oncogenic transcriptional program driven by SETBP1 mutations in leukemia.
The discovery that MECOM is a direct downstream target of SETBP1, and that this relationship is confirmed in patient samples, also provides a potential biomarker: measuring MECOM expression in SETBP1-mutant leukemias could be a clinically useful indicator of disease activity and treatment response.